Humacyte (HUMA)
NASDAQ:HUMA
Want to see HUMA full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted tangible commercial momentum (Symvess unit and revenue growth), strengthened commercial leadership, international regulatory progress (Israel MAA accepted), strategic government interest (DoD funding), and important near-term clinical catalysts (V012 interim results due June 11 and CTEV Phase I/II planned H2 2026). These operational and pipeline advances were balanced against financial headwinds in the quarter: a swing to a $17.6M net loss driven largely by reduced noncash other income, a large inventory reserve that inflated COGS, increased R&D spend for CTEV manufacturing, and modest absolute product revenue despite high percentage growth. The company has taken actions (restructuring, senior hires, targeted commercialization) to address uptake and cost structure and reported a cash position of $48.9M. Overall, progress on product, pipeline, and commercialization initiatives combined with cost-saving actions and an upcoming trial readout lead to a cautiously optimistic view of the company’s near-term prospects, tempered by the recent negative impact on profitability and remaining timing uncertainties around regulatory and procurement milestones.Company Guidance
Symvess Commercial Growth
Symvess sales grew to $0.5M in Q1 2026 from $0.1M in Q1 2025 (+400%), with units rising to 29 from 5 (+480%). Management reported sequential unit growth and expanding usage across ~30+ sites with evidence of colleague adoption beyond initial index surgeons.
Dialysis Phase III (V012) Progress and Near-Term Milestone
V012 enrollment reached 120 patients; prespecified interim topline results are expected for presentation by June 11, 2026 (Vascular Annual Meeting). If positive, the trial will stop per protocol and Humacyte plans a supplemental BLA submission for dialysis in H2 2026.
CTEV (Coronary Tissue Engineered Vessel) Advancement
IND for CTEV was submitted in late 2025, first large-scale manufacturing lot is nearing completion in the commercial facility, and a Phase I/II CABG trial is planned to commence in H2 2026. Vessels are 3.5 mm diameter, tailored for coronary use.
Commercial Leadership Strengthening
Company added senior commercial and clinical leaders to accelerate launch: James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer, plus expanded field commercial talent focused on IDNs and surgeon education.
International and Strategic Engagements
Submitted MAA for Israel which was accepted for review (180 working-day review); announced $1.475M purchase commitment from the Kingdom of Saudi Arabia to support clinical evaluation and outreach; received dedicated U.S. Department of Defense funding for evaluation and incorporation of biologic vascular repair technologies; regained ex-U.S. rights enabling outreach to Middle East, Europe and Japan.
Restructuring, Cost Savings and Cash Position
Implemented workforce reduction of 45 employees (~25%) to focus resources on commercialization; estimated one-time severance and termination benefits of ~$0.8M (mostly Q2 2026) and projected net savings of ~$14.3M for remainder of 2026. Cash, cash equivalents and restricted cash were $48.9M as of March 31, 2026; net cash used of $2.0M in Q1 2026.
HUMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HUMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $0.91 | $1.13 | +24.18% |
Mar 27, 2026 | $0.78 | $0.68 | -13.24% |
Nov 12, 2025 | $1.28 | $1.25 | -2.34% |
Aug 11, 2025 | $2.48 | $1.75 | -29.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Humacyte (HUMA) report earnings?
Humacyte (HUMA) is schdueled to report earning on Aug 17, 2026, Before Open (Confirmed).
What is Humacyte (HUMA) earnings time?
Humacyte (HUMA) earnings time is at Aug 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HUMA EPS forecast?
HUMA EPS forecast for the fiscal quarter 2026 (Q2) is -0.11.